Sign In
Buy RPTX
$2.65
+0 (+0%)
At Close: Apr 24, 2026
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:55am, Friday, 24'th Jan 2025
Repare Therapeutics (RPTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 21'st Jan 2025
Repare Therapeutics (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
04:05pm, Thursday, 09'th Jan 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions.
Why Is Repare Therapeutics Stock Trading Lower On Friday?
12:09pm, Friday, 13'th Dec 2024
On Thursday, Repare Therapeutics Inc RPTX revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cance
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
04:05pm, Tuesday, 10'th Dec 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
07:05am, Tuesday, 12'th Nov 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
07:05am, Thursday, 07'th Nov 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results.
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
06:05am, Wednesday, 23'rd Oct 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
10:05am, Tuesday, 15'th Oct 2024
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
07:05am, Monday, 14'th Oct 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers.
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
06:13pm, Friday, 30'th Aug 2024
Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expecte
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
04:05pm, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio.
